Table 2.
Patient Demographic and Clinical Characteristics
| Characteristic | HDC (n = 3,118) |
Control (n = 3,092) |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| Age, years | ||||
| Median | 46.2 | 46 | ||
| Range | 21.7-66.1 | 20.6-67.0 | ||
| Menopausal status | ||||
| Pre | 2,146 | 68.8 | 2,134 | 69.0 |
| Post | 922 | 29.6 | 906 | 29.3 |
| Missing | 50 | 1.6 | 52 | 1.7 |
| ER status | ||||
| Negative | 1,024 | 32.8 | 1,043 | 33.7 |
| Positive | 1,415 | 45.4 | 1,382 | 44.7 |
| Missing | 679 | 21.8 | 667 | 21.6 |
| PR status | ||||
| Negative | 1,088 | 34.9 | 1,070 | 34.6 |
| Positive | 1,233 | 39.5 | 1,226 | 39.7 |
| Missing | 797 | 25.6 | 796 | 25.7 |
| HmR status | ||||
| Negative | 1,032 | 33.1 | 1,046 | 33.8 |
| Positive | 1,552 | 49.8 | 1,522 | 49.2 |
| Missing | 534 | 17.1 | 524 | 16.9 |
| HER2 status | ||||
| Negative | 648 | 20.8 | 612 | 19.8 |
| Positive | 220 | 7.1 | 215 | 7.0 |
| Missing | 2,250 | 72.2 | 2,265 | 73.3 |
| Histologic grade | ||||
| Low | 141 | 4.5 | 127 | 4.1 |
| Medium | 577 | 18.5 | 598 | 19.3 |
| High | 835 | 26.8 | 780 | 25.2 |
| Missing | 1,565 | 50.2 | 1,587 | 51.3 |
| Histologic type | ||||
| Invasive ductal | 1,227 | 39.4 | 1,215 | 39.3 |
| Invasive lobular | 242 | 7.8 | 257 | 8.3 |
| Mixed | 62 | 2.0 | 52 | 1.7 |
| Other | 108 | 3.5 | 104 | 3.4 |
| Missing | 1,479 | 47.4 | 1,464 | 47.3 |
| Positive lymph nodes | ||||
| < 10 | 1,157 | 37.1 | 1,119 | 36.2 |
| ≥ 10 | 1,943 | 62.3 | 1,947 | 63.0 |
| Missing | 18 | 0.6 | 26 | 0.8 |
| Tumor size, cm | ||||
| Median | 3.0 | 2.7 | ||
| Range | 0.01-17.5 | 0.03-20.0 | ||
| Assigned tamoxifen | ||||
| HmR negative | ||||
| No. | 170 | 16.5 | 170 | 16.3 |
| Total No. | 1,032 | 1,046 | ||
| HmR positive | ||||
| No. | 1,463 | 94.3 | 1,429 | 93.9 |
| Total No. | 1,551 | 1,522 | ||
| HmR missing | ||||
| No. | 484 | 90.6 | 470 | 89.7 |
| Total No. | 534 | 524 | ||
Abbreviations: HER2, human epidermal growth factor receptor 2; HDC, high-dose chemotherapy; HmR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor.